Scarica l'app Stockscreener
28.15
2.09%
-0.60
Pre-mercato:
28.70
0.55
+1.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Tritonpoint Wealth LLC - MarketBeat
Should You Bet on Castle Biosciences? The Truth Behind Its Stock Struggles! - Jomfruland.net
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Vanguard Group Inc. Increases Stake in Castle Biosciences Inc. - GuruFocus.com
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for CSTL Earnings - Defense World
JPMorgan Chase & Co. Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
FY2024 Earnings Estimate for CSTL Issued By Leerink Partnrs - Defense World
Castle Biosciences (NASDAQ:CSTL) Trading 8.1% HigherTime to Buy? - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Buy" by Brokerages - MarketBeat
Castle Biosciences' DecisionDx-SCC Shows 92% Accuracy in Groundbreaking 1,400-Patient Cancer Study - StockTitan
Despite shrinking by US$214m in the past week, Castle Biosciences (NASDAQ:CSTL) shareholders are still up 29% over 1 year - Simply Wall St
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock - Investing.com India
Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock By Investing.com - Investing.com Australia
Castle Biosciences stock tumbles following guidance concerns - Investing.com India
Castle Biosciences stock tumbles following guidance concerns By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Trading Down 14%What's Next? - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Expects 50% Revenue Growth in 2024, Hits Record 96,000 Tests Despite Medicare Setback - StockTitan
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Milton Daily Standard
Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences stock falls following Medicare coverage denial By Investing.com - Investing.com Canada
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownHere's Why - MarketBeat
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 Shares - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares - MarketBeat
Castle Biosciences' chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Canada
Castle Biosciences’ chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences director Bradbury sells shares worth $229,225 By Investing.com - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 - Investing.com India
Castle Biosciences director Bradbury sells shares worth $229,225 - Investing.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Up 6.2%Here's Why - MarketBeat
Castle Biosciences gains NY approval for esophageal test By Investing.com - Investing.com Nigeria
Castle Biosciences gains New York state approval for Barrett’s oesophagus test - Yahoo Finance
Castle Biosciences gains NY approval for esophageal test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test - Business Wire
Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World
Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga
5.26%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):